Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Nasal Spray Derived From Human Placenta Protects Against Alzheimer's Decline, Study in Mice Shows : ScienceAlert (opens in a new tab)

sciencealert.com · 2026-09-16

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 5 supported
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1

The story

Nasal Spray Derived From Human Placenta Protects Against Alzheimer's Decline, Study in Mice Shows : ScienceAlert

sciencealert.com · 2026-09-16

The story’s checkable claims.

Read the original story (opens in a new tab)
2

NewsLink checks it

Mostly supported

Every claim we could check holds up. Five of seven claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

  • 5 supported
  • 2 not covered
Open claim evidence
3
Source paper

Source layer

The 3 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

7 claims in this story

Showing all 7 claimsChoose a verdict to focus the list.

Claim 1 of 7Not coveredMice that received the spray twice a week for six months showed improved object recognition and spatial memory compared with controls.View evidenceHide evidence

Why this verdict

The abstract-level profile supports six months of treatment from 3 to 9 months of age and improved performance on object- and spatial-memory tests including NOR, OPR, and Y-maze. However, the stated dosing frequency of twice weekly is not provided in the abstract-level profile, so that detail is not verifiable at this depth.

1

Study evidence

Intranasally delivered hAMSC-EVs reached the hippocampus and were internalized by neurons and microglia.

“Female 3 × Tg-AD mice received chronic intranasal hAMSC-EV administration from 3 to 9 months of age.”
Claim 2 of 7Not coveredIn a separate lab experiment, neurons derived from skin cells of people with sporadic Alzheimer's disease showed reduced deterioration and restored expression of neuroplasticity-related proteins after EV treatment.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that sporadic AD patient-derived iPSC glutamatergic neurons treated with hAMSC-EVs showed prevention of neurite atrophy and rescue of synaptic protein expression. However, the profile does not verify that the original cells were skin cells, and it does not specify the exact protein set or label them as neuroplasticity-related at abstract depth.

1

Study evidence

hAMSC-EV treatment prevented neurite atrophy in glutamatergic neurons differentiated from sporadic AD patient iPSCs.

“Translational relevance of the hAMSC-EV effects was assessed in glutamatergic neurons differentiated from induced pluripotent stem cells derived from sporadic AD patients.”
Claim 3 of 7SupportedA new study in Translational Neurodegeneration suggests a nasal formulation made from extracellular vesicles derived from human placental cells could help counter inflammation linked to Alzheimer's disease.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that intranasal hAMSC-EVs derived from human amniotic membrane MSCs were tested in an Alzheimer’s mouse model and were associated with reduced neuroinflammatory markers. The story frames this as a hedged suggestion, not an established human therapy.

1

Study evidence

Intranasally delivered hAMSC-EVs reached the hippocampus and were internalized by neurons and microglia.

“Female 3 × Tg-AD mice received chronic intranasal hAMSC-EV administration from 3 to 9 months of age.”
2

Study evidence

hAMSC-EVs were isolated and characterized for size and marker profile.

“hAMSC-EVs were isolated and characterized for size, markers, and biodistribution.”
Claim 4 of 7SupportedThe researchers treated transgenic mice engineered to develop Alzheimer's-like features with a nasal spray containing human amniotic mesenchymal stromal cell-derived vesicles from the placental amniotic membrane.View evidenceHide evidence

Why this verdict

The paper profile reports chronic intranasal administration of hAMSC-EVs to female 3×Tg-AD mice, an Alzheimer’s disease mouse model. The source as human amniotic membrane MSC-derived EVs is consistent with the story’s description of placental amniotic membrane-derived vesicles.

1

Study evidence

Intranasally delivered hAMSC-EVs reached the hippocampus and were internalized by neurons and microglia.

“Female 3 × Tg-AD mice received chronic intranasal hAMSC-EV administration from 3 to 9 months of age.”
Claim 5 of 7SupportedThe treatment significantly reduced amyloid-beta deposits in the hippocampus, but did not seem to affect tau phosphorylation.View evidenceHide evidence

Why this verdict

The profile reports reduced hippocampal Aβ after hAMSC-EV treatment and no effect on tau phosphorylation. The story’s wording of amyloid-beta 'deposits' is slightly more specific than the profile’s 'Aβ levels,' but the main claim matches the abstract-level findings.

1

Study evidence

Intranasally delivered hAMSC-EVs reached the hippocampus and were internalized by neurons and microglia.

“Female 3 × Tg-AD mice received chronic intranasal hAMSC-EV administration from 3 to 9 months of age.”
Claim 6 of 7SupportedTreated animals also had lower signs of neuroinflammation, with reduced activation of astrocytes and microglia, and higher levels of neuroplasticity-related proteins such as ARC, GluA1, and BDNF.View evidenceHide evidence

Why this verdict

The profile reports attenuation of neuroinflammation with reduced microglial and astrocytic measures, microglial remodeling, anti-inflammatory cytokine shifts, and increased neuroplasticity/synaptic proteins including BDNF, GluA1, and ARC. This aligns with the story claim.

1

Study evidence

Intranasally delivered hAMSC-EVs reached the hippocampus and were internalized by neurons and microglia.

“Female 3 × Tg-AD mice received chronic intranasal hAMSC-EV administration from 3 to 9 months of age.”
Claim 7 of 7SupportedThe researchers caution that these are preclinical results that still require validation in humans and are not yet an available therapy for Alzheimer's disease.View evidenceHide evidence

Why this verdict

The paper profile describes preclinical evidence from mice and ex vivo human iPSC-derived neurons, not a human clinical therapy. The caveat that human validation is still needed and that this is not yet an available Alzheimer’s treatment is consistent with the evidence base and limitations.

1

Study evidence

Intranasally delivered hAMSC-EVs reached the hippocampus and were internalized by neurons and microglia.

“Female 3 × Tg-AD mice received chronic intranasal hAMSC-EV administration from 3 to 9 months of age.”
2

Study evidence

hAMSC-EV treatment prevented neurite atrophy in glutamatergic neurons differentiated from sporadic AD patient iPSCs.

“Translational relevance of the hAMSC-EV effects was assessed in glutamatergic neurons differentiated from induced pluripotent stem cells derived from sporadic AD patients.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • EV characterization and biodistribution: hAMSC-EVs were isolated/characterized and intranasally delivered EVs reached the hippocampus and were internalized by neurons and microglia.

    The story reflects the EV source and nasal delivery but does not report the paper’s feasibility/biodistribution evidence that EVs reached the hippocampus and were taken up by neurons and microglia.

    From in_vivo_biodistribution_and_EV_characterization

  • In silico miRNA cargo analysis found hAMSC-EV miRNAs enriched in immunomodulatory and neuroprotective pathways.

    The story does not appear to cover the bioinformatic miRNA cargo/pathway-enrichment analysis, which the paper uses as mechanism-supporting evidence.

    From in_silico bioinformatic enrichment

4 things the story did carry across
  • Central in vivo study: chronic intranasal hAMSC-EV treatment in female 3×Tg-AD mice from 3 to 9 months, with behavioral and hippocampal pathology/inflammation endpoints.
  • Human cellular translational model: sporadic AD patient-derived iPSC glutamatergic neurons were treated with hAMSC-EVs, preventing neurite atrophy and rescuing synaptic protein expression without affecting viability.
  • Important limitation: tau phosphorylation was not affected despite reduced Aβ, limiting claims of broad disease-modifying impact.
  • Preclinical/translational caveat: mouse and ex vivo human-cell results do not establish efficacy or availability as a human Alzheimer’s therapy.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalTest whether chronic intranasal administration of human amniotic membrane MSC-derived extracellular vesicles (hAMSC-EVs) prevents cognitive decline and neuropathology/neuroinflammation in an Alzheimer’s disease mouse model.in vivo animal efficacy study (female 3×Tg-AD mice, chronic intranasal EV treatment)Expand

In plain English

Chronic intranasal administration of extracellular vesicles derived from human amniotic membrane mesenchymal stromal cells (hAMSC-EVs) to female 3×Tg-AD mice from 3 to 9 months of age was associated with delivery of EVs to the hippocampus (internalization by neurons and microglia), improved performance on object- and spatial-memory behavioral tests, reduced hippocampal Aβ levels without changes in tau phosphorylation, attenuation of glial activation and microglial remodeling, a shift toward an anti-inflammatory cytokine profile, and increased expression of hippocampal neuroplasticity/synaptic proteins (BDNF, GluA1, ARC).

Key findings

  • Intranasally delivered hAMSC-EVs reached the hippocampus and were internalized by neurons and microglia.
  • Chronic intranasal hAMSC-EV treatment improved cognitive performance of female 3×Tg-AD mice on novel object recognition, object place recognition, and Y-maze tests.
“Female 3 × Tg-AD mice received chronic intranasal hAMSC-EV administration from 3 to 9 months of age.”
What this piece can’t prove

4 further details could not be confirmed from the summary.

2in vivo animalEstablish EV isolation/characterization and in vivo biodistribution/brain cell uptake after intranasal delivery as mechanistic/feasibility support for the therapeutic effect.in vivo biodistribution and EV characterizationExpand

In plain English

The study reports isolation and bench characterization of extracellular vesicles (EVs) derived from human amniotic membrane mesenchymal stromal cells (hAMSC-EVs) for size and marker profile, and shows that intranasally delivered hAMSC-EVs reach the hippocampus and are internalized by neurons and microglia in the treated animals. These data are presented as mechanistic/feasibility support for downstream therapeutic effects in AD models, with endpoints focused on EV properties and localization rather than quantitative biodistribution metrics or detailed methodological parameters in the abstract.

Key findings

  • hAMSC-EVs were isolated and characterized for size and marker profile.
  • Intranasally delivered hAMSC-EVs reached the hippocampus and were internalized by neurons and microglia.
“hAMSC-EVs were isolated and characterized for size, markers, and biodistribution.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

3ex vivo humanAssess translational relevance in a human cellular AD model (iPSC-derived glutamatergic neurons from sporadic AD patients), testing whether hAMSC-EVs protect neurites and synaptic proteins.ex vivo humanExpand

In plain English

In an ex vivo human translational model, glutamatergic neurons differentiated from iPSCs derived from sporadic AD patients were treated with extracellular vesicles from human amniotic membrane MSCs (hAMSC-EVs). According to the abstract, hAMSC-EV treatment prevented neurite atrophy and rescued synaptic protein expression in these human AD neurons while not affecting cell viability.

Key findings

  • hAMSC-EV treatment prevented neurite atrophy in glutamatergic neurons differentiated from sporadic AD patient iPSCs.
  • hAMSC-EVs rescued synaptic protein expression in human AD iPSC-derived neurons.
“Translational relevance of the hAMSC-EV effects was assessed in glutamatergic neurons differentiated from induced pluripotent stem cells derived from sporadic AD patients.”
What this piece can’t prove
  • Results derive from an ex vivo human neuronal model and may not capture effects present in intact brain tissue or in vivo systems.

3 further details could not be confirmed from the summary.

4in silicoCharacterize/interpret hAMSC-EV miRNA cargo via bioinformatic enrichment to support immunomodulatory/neuroprotective mechanism hypotheses.in silico bioinformatic enrichmentExpand

In plain English

The authors performed in silico bioinformatic analyses of the miRNA cargo of human amniotic MSC-derived extracellular vesicles (hAMSC-EVs). From the abstract, these analyses are reported to identify enrichment of EV miRNA cargoes in immunomodulatory and neuroprotective pathways. The abstract does not provide details on the input data source (new sequencing versus existing datasets), specific miRNAs, enrichment methods, pathway databases, or statistical metrics.

Key findings

  • Bioinformatic analyses of hAMSC-EV miRNA cargo identified enrichment in immunomodulatory and neuroprotective pathways.
“Bioinformatic analyses were performed to investigate the miRNA cargoes of hAMSC-EVs.”
What this piece can’t prove
  • Enrichment findings are correlative/inferential and not experimentally validated within the described bioinformatic analysis.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 17 candidate papers

SelectedOpen access

Human amniotic mesenchymal stromal cell-derived extracellular vesicles reprogram microglia and prevent neurodegeneration in experimental models of Alzheimer's disease.

Translational Neurodegeneration · 2026 · PubMed, Europe PMC, Crossref

Tessa (opens in a new tab)Source (opens in a new tab)
Candidate

Small RNA-seq of extracellular vesicles secreted from human amniotic fluid mesenchymal stromal cells

BioStudies Database · Crossref

Source (opens in a new tab)

And 11 more candidates considered.